A Phase 1/2, Active-controlled, Randomized, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Oral Doses of OPC-167832 Tablets in Subjects With Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Delamanid (Primary) ; OPC-167832 (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 23 Apr 2019 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
- 23 Apr 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.